DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on April 30, 2007; DOI: 10.1124/dmd.106.012930


0090-9556/07/3508-1308-1314$20.00
DMD 35:1308-1314, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012930v1
35/8/1308    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Noé, J.
Right arrow Articles by Funk, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Noé, J.
Right arrow Articles by Funk, C.

Substrate-Dependent Drug-Drug Interactions between Gemfibrozil, Fluvastatin and Other Organic Anion-Transporting Peptide (OATP) Substrates on OATP1B1, OATP2B1, and OATP1B3

Johannes Noé, Renée Portmann, Marie-Elise Brun, and Christoph Funk

F. Hoffmann-La Roche Ltd., Non-Clinical Development-Drug Safety, Basel, Switzerland

Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic elimination of many drugs and potentially associated drug-drug interactions. The gemfibrozil-statin interaction was studied at the level of active hepatic uptake as a model for such drug-drug interactions. Active, temperature-dependent uptake of fluvastatin into primary human hepatocytes was shown. Multiple transporters are involved in this uptake as Chinese hamster ovary or HEK293 cells expressing either OATP1B1 (Km = 1.4–3.5 µM), OATP2B1 (Km = 0.7–0.8 µM), or OATP1B3 showed significant fluvastatin uptake relative to control cells. For OATP1B1 the inhibition by gemfibrozil was substrate-dependent as the transport of fluvastatin (IC50 of 63 µM), pravastatin, simvastatin, and taurocholate was inhibited by gemfibrozil, whereas the transport of estrone-3-sulfate and troglitazone sulfate (both used at 3 µM) was not affected. The OATP1B1- but not OATP2B1-mediated transport of estrone-3-sulfate displayed biphasic saturation kinetics, with two distinct affinity components for estrone-3-sulfate (0.23 and 45 µM). Only the high-affinity component was inhibited by gemfibrozil. Recombinant OATP1B1-, OATP2B1-, and OATP1B3-mediated fluvastatin transport was inhibited to 97, 70, and 62% by gemfibrozil (200 µM), respectively, whereas only a small inhibitory effect by gemfibrozil (200 µM) on fluvastatin uptake into primary human hepatocytes was observed (27% inhibition). The results indicate that the in vitro engineered systems can not always predict the behavior in more complex systems such as freshly isolated primary hepatocytes. Therefore, selection of substrate, substrate concentration, and in vitro transport system are critical for the conduct of in vitro interaction studies involving individual liver OATP carriers.


Address correspondence to: Dr. Christoph Funk, F. Hoffmann-La Roche Ltd., Non-Clinical Development-Drug Safety; 69/154, 4070 Basel, Switzerland. E-mail: christoph.funk{at}roche.com




This article has been cited by other articles:


Home page
EndocrinologyHome page
D. E. Westholm, D. R. Salo, K. J. Viken, J. N. Rumbley, and G. W. Anderson
The Blood-Brain Barrier Thyroxine Transporter Organic Anion-Transporting Polypeptide 1c1 Displays Atypical Transport Kinetics
Endocrinology, November 1, 2009; 150(11): 5153 - 5162.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
S. Leuthold, B. Hagenbuch, N. Mohebbi, C. A. Wagner, P. J. Meier, and B. Stieger
Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters
Am J Physiol Cell Physiol, March 1, 2009; 296(3): C570 - C582.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. Poirier, T. Lave, R. Portmann, M.-E. Brun, F. Senner, M. Kansy, H.-P. Grimm, and C. Funk
Design, Data Analysis, and Simulation of in Vitro Drug Transport Kinetic Experiments Using a Mechanistic in Vitro Model
Drug Metab. Dispos., December 1, 2008; 36(12): 2434 - 2444.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Grime, P. J. H. Webborn, and R. J. Riley
Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes
Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.